Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Breast Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 23Neoplasms 22Multiple Myeloma 18Leukemia, Myeloid, Acute 14Neoplasm Metastasis 11Carcinoma, Renal Cell 10Leukemia 10Melanoma 10Ovarian Neoplasms 10Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Adenocarcinoma 8Carcinoma, Hepatocellular 8Colorectal Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lung Neoplasms 8Myelodysplastic Syndromes 8Prostatic Neoplasms 8Stomach Neoplasms 8Lymphoma, Follicular 7Bronchiolitis Obliterans Syndrome 6Carcinoma 6Lymphoma 6Lymphoma, Non-Hodgkin 6Small Cell Lung Carcinoma 6Urinary Bladder Neoplasms 6Cholangiocarcinoma 5

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Has announcements × Hematologic Neoplasms × Clear all
NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Gamida Cell ltd

Phase 3 Completed
125 enrolled 18 charts 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Celgene

Phase 1/2 Completed
345 enrolled 120 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡